This web page contains forward-looking statements, including, without limitation, statements containing the words “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “continue” and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results.

By their nature, such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements contained in this web page.

Important factors that could result in such differences include but are not limited to: the global spread and impact of COVID-19, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws, and hiring and retention of its employees.

There is no guarantee that new product candidates will be discovered or identified in the pipeline, or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB’s efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB’s products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products.

Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. There can be no guarantee that the investigational or approved products potentially described in this web page will be submitted or approved for sale or for any additional indications or labelling in any market, or at any particular time, nor can there be any guarantee that such products will be or will continue to be commercially successful in the future. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB’s data and systems.

Given these uncertainties, the public is cautioned not to place any undue reliance on such forward-looking statements. These forward-looking statements are made only as of the date of web page, and do not reflect any potential impacts from the evolving COVID-19 pandemic, unless indicated otherwise. UCB continues to follow the development diligently to assess the financial significance of this pandemic to UCB. Information contained in this web page shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any offer, solicitation or sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction.

In the event of any differences between this web page and the Integrated Annual Report or Half Year Report, the information included in the Report shall prevail.

		Reaching more than 151 000 patients across 58 countries (Dec 2020)
		Axial spondylarthritis Crohn's disease Psoriasis Psoriatic arthritis Rheumatoid arthritis
		Astellas (Japan - 2012) Cinkate (China – 2019)
		2024 Europe & U.S. 2026 in Japan
		1 799 million in 2020 ≥ 2 billion expected peak sales by 2024
		Latest approvals Psoriasis / psoriatic arthritis  (Japan - Dec 2019) Rheumatoid arthritis  (China - July 2019) Non-radiographic axial spondylarthritis  (U.S. - Mar 2019)

axial spondyloarthritis (AxSpA) - prescribing information

Crohn's disease (CD)- prescribing information

psoriasis (PsO) - prescribing information

psoriatic arthritis (PsA) - prescribing information 

rheumatoid arthritis (RA) - prescribing information

		Reaching more than 734 000 patients across 52 countries (Dec 2020)
		Epilepsy POS1 Epilepsy PGTCS2
		Daiichi-Sankyo (Japan - 2014)
		2022 Europe & U.S. 2024 in Japan
		1 451 million in 2020 ≥ 1.5 billion expected peak sales by 2022
		Latest approvals Epilepsy PGTCS2 (U.S. - Nov 2020 / EU & Japan – Dec 2020)
		Latest filings Epilepsy POS1 pediatric - adj. therapy (China - Sept 2018)

1 POS: partial-onset seizure, also known as focal seizure

2 PGTCS: primary generalized tonic-clonic seizures

Vimpat^® prescribing information

		Reaching more than 2.1 million patients across the world
		Epilepsy POS1 Epilepsy PGTCS2 Epilepsy myoclonic seizures
		Otsuka (Japan - 2008-2020)
		U.S. - 2008 Europe - 2010 Japan - 2020
		788 million in 2020 1.2 billion peak sales (2008)

1 POS: partial-onset seizure, also known as focal seizure

2 PGTCS: primary generalized tonic-clonic seizures

Keppra® prescribing information